Anthracycline-induced cardiotoxicity: A review of pathophysiology, diagnosis, and treatment

被引：144

作者：

Raj S. ^{[1
,2
]}

Franco V.I. ^{[3
]}

Lipshultz S.E. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Department of Pediatrics, Division of Pediatric Cardiology, University of Miami Miller School of Medicine, Miami, FL

[2] Holtz Children's Hospital, University of Miami, Jackson Memorial Medical Center, Miami, FL

[3] Division of Pediatric Clinical Research, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL

[4] Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

[5] Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI 48201

来源：

Current Treatment Options in Cardiovascular Medicine | 2014年 / 16卷 / 6期

关键词：

Anthracycline; Cardiomyopathy; Childhood cancer survivor; Dexrazoxane; Left ventricular dysfunction;

D O I：

10.1007/s11936-014-0315-4

中图分类号：

学科分类号：

摘要：

Anthracyclines have been widely used in children and adults to treat hematologic malignancies, soft-tissue sarcomas, and solid tumors. However, anthracyclines come with both short- and long-term cardiotoxic effects, ranging from occult changes in myocardial structure and function to severe cardiomyopathy and heart failure that may result in cardiac transplantation or death. Here, we review the progress made over the past two decades in understanding the molecular and genetic basis of anthracycline-induced cardiotoxicity; detecting and monitoring myocardial dysfunction; using adjunct cardioprotectant therapies, such as dexrazoxane; and improving cardioprotection with agents such as liposomal and pegylated doxorubicin. Despite this increased understanding, preventing drug-induced cardiotoxicity while maintaining oncologic efficacy to achieve the highest quality of life over a lifespan remain cornerstones of successful anthracycline chemotherapy during childhood. © 2014 Springer Science+Business Media.

引用

共 75 条

[1]

American Cancer Society. Cancer Facts and Figures 2013, (2013)

[2]

Howlader N., Noone A.M., Krapcho M., Et al., SEER Cancer Statistics Review, 1975-2010

[3]

Lipshultz S.E., Adams M.J., Colan S.D., Et al., Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: Pathophysiology, course, monitoring, management, prevention, and research directions: A scientific statement from the American Heart Association, Circulation, 128, pp. 1927-1995, (2013)

[4]

Lipshultz S.E., Alvarez J.A., Scully R.E., Anthracycline associated cardiotoxicity in survivors of childhood cancer, Heart, 94, 4, pp. 525-533, (2008)

[5]

Mulrooney D.A., Yeazel M.W., Kawashima T., Et al., Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort, BMJ, 339, (2009)

[6]

Pein F., Sakiroglu O., Dahan M., Lebidois J., Merlet P., Shamsaldin A., Villain E., De Vathaire F., Sidi D., Hartmann O., Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy, British Journal of Cancer, 91, 1, pp. 37-44, (2004)

[7]

Van Dalen E.C., Van Der Pal H.J.H., Kok W.E.M., Caron H.N., Kremer L.C.M., Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study, European Journal of Cancer, 42, 18, pp. 3191-3198, (2006)

[8]

Sorensen K., Levitt G., Bull C., Chessells J., Sullivan I., Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity, Journal of Clinical Oncology, 15, 1, pp. 61-68, (1997)

[9]

Lipshultz S.E., Colan S.D., Gelber R.D., Et al., Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood, N Engl J Med, 324, pp. 808-815, (1991)

[10]

Kremer L.C.M., Van Der Pal H.J.H., Offringa M., Van Dalen E.C., Voute P.A., Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review, Annals of Oncology, 13, 6, pp. 819-829, (2002)

← 1 2 3 4 5 6 7 8 →